Assets (1 total) 1 Total Assets
0 Approved
0 Phase 3 / Filed
1 Phase 1–2 / Early
1 Diseases
Disease: All diseases (1) Non-Small Cell Lung Cancer (1)
Stage: All stages (1) Approved / Phase 4 (0) Phase 3 / Filed (0) Phase 2 Phase 1 / Preclinical
Showing 1 of 1 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 2 IGSF8 Monoclonal antibody
Non-Small Cell Lung Cancer
Upcoming events (3 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (1) December 2026 (1) GV20-0251 Phase 1/2 Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma … Est. primary completion 2026-12-15 ·
NCT05669430 ·
CT.gov ↗ What to watch
2027 (1) July 2027 (1) GV20-0251 Phase 1/2 Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma … Est. primary completion 2027-07-16 ·
NCT07070518 ·
CT.gov ↗ What to watch
2028 (1) June 2028 (1) GV20-0251 Phase 2 Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck … Est. primary completion 2028-06-15 ·
NCT07623642 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Financial reports No financial reports recorded.